Physician profile
Millard D Collins
NPI 1952389173
$1,679.58
in general payments reported to CMS, 2019-2025
27 companies · $24.05 in 2025
The $24.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.31 · 2020: $164 · 2021: $226 · 2022: $326 · 2023: $686 · 2024: $185 · 2025: $24.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $341.46 | 2021-2023 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $211.66 | 2023-2024 | Nuedexta, Rexulti |
| Pfizer INC. | $206.78 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $157.94 | 2022 | |
| Alkermes, INC. | $110.66 | 2019-2025 | Lybalvi, Vivitrol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.46 | 2020 | |
| Abbvie INC. | $59.40 | 2024 | |
| Neurelis, INC. | $53.56 | 2023-2024 | Valtoco |
| Avanir Pharmaceuticals, INC. | $48.81 | 2022 | |
| Novo Nordisk INC | $42.24 | 2020-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $38.19 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $37.24 | 2022-2023 | |
| Kerecis Limited | $32.90 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| E.R. Squibb & Sons, L.L.C. | $29.73 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.19 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.71 | 2024 | |
| Lundbeck LLC | $22.59 | 2023 | Rexulti |
| Exact Sciences Corporation | $22.08 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.80 | 2023 | |
| Lilly USA, LLC | $17.64 | 2023 | Basaglar, Trulicity |
| Glaxosmithkline, LLC. | $17.49 | 2022 | |
| Sumitomo Pharma America, INC. | $16.68 | 2023 | Gemtesa |
| Depuy Synthes Sales INC. | $15.80 | 2024 | Monovisc, Orthovisc |
| Medtronic, INC. | $15.27 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.50 | 2022 | |
| Urovant Sciences INC | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millard Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.